Rimbau V, Fernández E, Torralba A, Sabater J
Arzneimittelforschung. 1983;33(6):831-3.
The comparative gastrointestinal (GI) tolerability of 4'-acetamidophenyl-2-(5'-p-toluyl-1'-methylpyrrole) acetate (AU-8001), tolmetin and placebo have been studied in rat through a radioactive quantification method with Fe-59 of the GI microbleeding. The drugs were given orally at equimolecular doses of AU-8001 and sodium tolmetin equivalent to 100 mg/kg/day of tolmetin acid. Four days administration of sodium tolmetin induced significant increases of fecal radioactivity (p less than 0.005) whereas no difference was observed between animals treated with equimolecular doses of AU-8001 and control animals. The fecal elimination of radioactivity in the animals treated with sodium tolmetin was also significantly higher than in animals receiving AU-8001 (p less than 0.02).
通过用铁-59对胃肠道微出血进行放射性定量的方法，在大鼠中研究了4'-乙酰氨基苯基-2-(5'-对甲苯基-1'-甲基吡咯)乙酸酯(AU-8001)、托美汀和安慰剂的相对胃肠道(GI)耐受性。以相当于100mg/kg/天托美汀酸的AU-8001和托美汀钠等分子剂量口服给药。托美汀钠给药四天导致粪便放射性显著增加(p<0.005)，而等分子剂量的AU-8001治疗的动物与对照动物之间未观察到差异。托美汀钠治疗的动物粪便放射性消除也显著高于接受AU-8001的动物(p<0.02)。
